Fusion inhibitors: T-20 and T-1249.
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D002170:Canada; D002986:Clinical Trials as Topic; D000077560:Enfuvirtide; D005260:Female; D006678:HIV / Q000502:physiology*; D015700:HIV Envelope Protein gp41 / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D008297:Male; D008561:Membrane Fusion / Q000187:drug effects*; D010446:Peptide Fragments / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D010446:Peptide Fragments; C102014:peptide T21; D000077560:Enfuvirtide